Ra Pharmaceuticals

General Information

We are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system. Inappropriate activation of the complement system can quickly turn it from a beneficial defense system to an aggressor that plays a major role in immune and inflammatory diseases. We are developing our lead product candidate, RA101495, a convenient self-administered subcutaneous, or SC, injection, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH. PNH is a rare, chronic, life-threatening, blood disorder where red blood cells are mistakenly attacked and destroyed by the complement system.

Employees: 40
Founded: 2008
Contact Information
Address 87 Cambridge Park Drive, Cambridge, MA 02140, US
Phone Number (617) 401-4060
Web Address https://www.rapharma.com
View Prospectus: Ra Pharmaceuticals
Financial Information
Market Cap $263.1mil
Revenues $6.8 mil (last 12 months)
Net Income $-16.7 mil (last 12 months)
IPO Profile
Symbol RARX
Exchange NASDAQ
Shares (millions): 5.8
Price range $12.00 - $14.00
Est. $ Volume $75.4 mil
Manager / Joint Managers Credit Suisse/ Jefferies/ BMO Capital Markets
CO-Managers SunTrust Robinson Humphrey
Expected To Trade: 10/26/2016
Day: Wednesday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change